Biasca, Switzerland, May 7, 2025 – HAS Healthcare Advanced Synthesis SA (“HAS”), a leading international developer and producer of active pharmaceutical ingredients (APIs), high-potency active pharmaceutical ingredients (HPAPIs), and anticancer compounds, is pleased to announce today the successful completion of its previously announced acquisition of Cerbios-Pharma SA (Cerbios), a globally recognised manufacturer of chemical and biological APIs, including in the rapidly expanding area of antibody drug conjugates (ADCs).

This strategic transaction marks a significant milestone for the two companies and sets the stage for the creation of a leading global solutions provider in the Contract Development and Manufacturing Organization (CDMO) industry.

The acquisition is backed by 65 Equity Partners, a global investment firm dedicated to supporting family-owned businesses, founders, and entrepreneurs. Through this transaction, 65 Equity Partners becomes a c.40% shareholder alongside the Braglia family who retain majority control.

The alliance of the two Swiss-based companies, both with a global market presence, will drive innovation, accelerate extensive high-quality production capabilities, and deliver the cutting-edge chemical and biological expertise, technical excellence, and a wider range of services to address the dynamic needs of the global pharmaceutical industry.

The new group, driven by a dedicated workforce of over 400 people, embodies a strong corporate culture and family ownership values that have long defined both companies, with a firm commitment to Switzerland’s Ticino region remaining at its core.

The two companies have now united their forces, maintaining the highest standards of quality and service, ensuring seamless integration and continued support for all customers with the same enthusiasm and commitment to excellence, enabling them to achieve new and significant milestones.